WADA is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
The metabolism of propionyl-CoA occurs in the mitochondria and requires Vitamin B12 (as adenosylcobalamin) to make succinyl-CoA. When the conversion of propionyl-CoA to succinyl-CoA in the mitochondria fails due to Vitamin B12 deficiency, elevated blood levels of methylmalonic acid (MMA) occur. Thus, elevated blood levels of homocysteine and MMA may both be indicators of vitamin B12 deficiency. Adenosylcobalamin is needed as cofactor in methylmalonyl-CoA mutase—MUT enzyme. Processing of cholesterol and protein gives propionyl-CoA that is converted to methylmalonyl-CoA, which is used by MUT enzyme to make succinyl-CoA. Vitamin B12 is needed to prevent anemia, since making porphyrin and heme in mitochondria for producing hemoglobin in red blood cells depends on succinyl-CoA made by vitamin B12.
== Types == The two types of ochronosis are endogenous and exogenous. The endogenous variety is an autosomal-recessive disease, known as alkaptonuria, that is caused by a lack of homogentisate oxidase enzyme. Exogenous ochronosis is an avoidable dermatitis that can be caused by the topical application of compounds such as hydroquinone or phenols. It was first seen in 1912, when a patient who used phenol on a leg ulcer was found by Beddard and Plumtre to have this condition. Hydroquinone-induced exogenous ochronosis was found in 1975 by Findlay, who observed the condition in patients who used skin lightening creams containing the compound. The three clinical stages of exogenous ochronosis are:
=== Overdose === Acute overdose is often manifested by nausea, weakness, slow heart rate, dizziness, low blood pressure, and abnormal heart rhythms. Plasma, serum, or blood concentrations of verapamil and norverapamil, its major active metabolite, may be measured to confirm a diagnosis of poisoning in hospitalized patients or to aid in the medicolegal investigation of fatalities. Blood or plasma verapamil concentrations are usually in a range of 50–500 μg/L in persons on therapy with the drug, but may rise to 1–4 mg/L in acute overdose patients and are often at levels of 5–10 mg/L in fatal poisonings.
=== Calcium-sensing receptor (CaR) === The secretion of parathyroid hormone (PTH) is regulated by the interaction of the calcium-sensing receptor with calcium in the blood. The calcium-sensing receptor is present on the plasma membrane of the chief cells. The CaR is a G protein-coupled receptor, as part of the C family. The CaR is divided into three general domains. These include an NH2-terminal extracellular end, a COOH-terminal intracellular end, and seven transmembrane domains. The CaR interacts positively with phospholipase C (PLC) and adenylyl cyclase. The CaR includes phosphorylation sites for protein kinase C (PKC) and protein kinase A (PKA). The phosphorylation of the PLC is seen to inhibit the secretion of PTH due to high calcium levels in the blood. The function of the PKA sites is currently unknown.
Sources: en.wikipedia.org
== Function == FGFR1OP2, when fused with the fibroblast growth factor receptor 1 (FGFR1), is shown to cause myeloproliferative syndrome. The protein encoded by the FGFR1 gene belongs to the fibroblast growth factor receptor family. FGFRs usually contain an extracellular ligand binding domain, a single transmembrane domain, and an intracellular tyrosine kinase domain. The extracellular domain specifies which ligand the receptor will bind to and mediates ligand-induced receptor dimerization. When FGFR1OP2 is fused to FGFR1, it may exhibit constitutive kinase activity. Furthermore, FGFR1OP2 is possibly involved in some steps of the wound healing pathway.
==== Member of the Royal Victorian Order (MVO) ==== Christian Mary Bailey, Curator to The Prince of Wales. Frederick Booth, Chief Heraldic Painter, College of Arms. Ann Teresa Brown, , lately British Overseas Trade Board. Matthew Nicholas Butler, lately Assistant Private Secretary to The Prince of Wales Pamela Margaret Clark, Deputy Registrar, Royal Archives, Windsor Castle. Claire Elizabeth Hunter-Craig, Secretary, Household of The Duke of Edinburgh. Reginald Elliott, Higher Executive Officer, Crown Estate, Windsor. Valerie Winifred Hampton, Personal Secretary to Princess Alexandra, the Honourable Lady Ogilvy. Chief Yeoman Warder Norman William Jackson, HM Tower of London. Alexander Masson, Head Gamekeeper, Balmoral Estate. John Ronald Pepper, lately of Collingwood & Company Limited. Inspector Stephen Lionel Robinson, Royalty and Diplomatic Protection Department, Metropolitan Police. Eileen Margaret Sly, lately the Westminster Abbey Trust. William Albert Stewart, Head Warden, Palace of Holyroodhouse. Prudence Sarah Sutcliffe, Assistant Curator of the Print Room, Windsor Castle. Lieutenant Colonel Patrick John Tabor, lately Equerry to The Prince of Wales.
The association of anti-tobacco smoking research and public health measures with the Nazi leadership may have contributed to the lack of attention paid to these studies. They were also published in German and Dutch. These studies were widely ignored. In 1947 the British Medical Council held a conference to discuss the reason for the rise in lung cancer deaths; unaware of the German studies, they planned and started their own. Five case-control studies published in 1950 by researchers from the US and UK did draw widespread attention. The strongest results were found by "Smoking and carcinoma of the lung. Preliminary report", by Richard Doll and Austin Bradford Hill, and the 1950 Wynder and Graham Study, entitled "Tobacco Smoking as a Possible Etiologic Factor in Bronchiogenic Carcinoma: A Study of Six Hundred and Eighty-Four Proved Cases". These two studies were the largest, and the only ones to carefully exclude ex-smokers from their non-smokers group. The other three studies also reported that, to quote one, "smoking was powerfully implicated in the causation of lung cancer". The Doll and Hill paper reported that "heavy smokers were fifty times as likely as non-smokers to contract lung cancer".
== Measurements and tests == The nitrogen by o-phthaldialdehyde assay (NOPA) is used to measure available primary amino acids in grape juice using a spectrophotometer that can measure at 335 nm wavelength. Since the assay only measures primary amino acids, the results won't include proline or ammonia concentrations. Proline can be separately measured with an assay that uses ninhydrin to react with the amino acid in the presence of formic acid, yielding a compound that can be absorbed at 517 nm.
Silver nitrate is an inorganic compound with chemical formula AgNO3. It is a colorless solid that is a precursor to many other silver compounds. Silver nitrate is highly soluble in water but is poorly soluble in most organic solvents, except acetonitrile (111.8 g/100 g, 25 °C). Silver nitrate is the least expensive salt of silver; it offers several other advantages as well. It is non-hygroscopic (in contrast to silver fluoroborate and silver perchlorate). In addition, it is relatively stable to light, and it dissolves in numerous solvents, including water. The nitrate can be easily replaced by other ligands.
Sources: en.wikipedia.org
=== Physical Health === Viruses, bacteria, protists, fungi, and more may rapidly kill insects on farms. For example, Acheta domesticus densovirus resulted in millions of dollars in lost product and some farms losing their entire livestock population in outbreaks that have spanned 35 years of industry history in North America and the United States. Some insect diseases appear to be specific to single species or taxonomic groups within the insects, and thus may not spread between species, while others may be able to infect multiple farmed insect species if housed in the same facility. Humans can carry diseases from the outside world to farmed insects. For instance, the company Van de Ven had a pathogen outbreak that killed all of its Zophobas morio beetle larvae, and the breeders hypothesized that the disease may have been brought by human visitors. Accordingly, the International Platform for Insects as Food and Feed have developed guidance on hygiene procedures for farms with the goal of protecting consumer and animal health. More integration of the veterinary and pathology communities, which are staples of traditional vertebrate animal farming, with the new insect farming sector may result in improved animal health, increased biosecurity, and better consumer protection over time. Insects may be injured due to aggression or cannibalism. Low temperatures, disease, or poor nutrition may result in deformities during any stage of development.
=== Tandem Mobi === The Tandem Mobi is a smaller durable pump intended to be worn on the body or carried in clothing. It uses a 200-unit cartridge and is operated principally from a compatible smartphone app, while a physical button can deliver a preset bolus. The FDA cleared the pump in July 2023, and Tandem began its full United States launch in February 2024. The company obtained a CE mark for Mobi in 2025 and subsequently began introducing it in European markets.
Following a Round 22 61-point demolition at the hands of lower-placed Hawthorn, Thompson's job was under immense pressure. After a very public review of the club, it was decided that Thompson should keep his job as senior coach. After a shaky start to the 2007 season that led many supporters to believe that nothing had changed from the 2006 season, Thompson led Geelong to a massive 15 match winning streak (the biggest in a single season in club history) and a 106-point win against the Kangaroos in the Qualifying Final which is the 5th biggest finals winning margin in AFL/VFL history. The 2007 season then culminated in one of the biggest, if not the best highlight of Thompson's career, in both a coaching and footballer's role. Thompson coached Geelong to win the AFL premiership in the 2007 AFL Grand Final by more than 100 points, which was the highest winning margin in Grand Final history, against Port Adelaide Football Club at the MCG on 29 September. It was the club's first premiership since 1963, the year of Thompson's birth. After the Essendon Football Club decided not to give Thompson's former mentor, Kevin Sheedy, a renewal of contract, there was speculation that Mark Thompson would take up the senior coaching role at Essendon for the 2008 season. However, with trade week quickly approaching, the club instead appointed Matthew Knights to the position. After Geelong's record-breaking win in the grand final, Geelong under Thompson were red hot favourite to repeat their 2007 success in the 2008 season and their form during the year did nothing to change that.
==== Other applications ==== Other MALS applications include nanoparticle sizing, protein aggregation studies, protein-protein interactions, electrophoretic mobility or zeta potential. MALS techniques have been adopted for the study of pharmaceutical drug stability, crystal nucleation and crystallization kinetics and use in nanomedicine.
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.